Skip to main content
Advertising

Originally published Friday, January 10, 2014 at 8:04 PM

  • Share:
           
  • Comments (14)
  • Print

Planned Medicare drug change stirs access worries

Some advocates for patients are criticizing the idea, but the Medicare prescription benefit’s first administrator says greater availability of generic drugs nowadays may allow for some protections to be safely eased.


The Associated Press

Most Popular Comments
Hide / Show comments
Oh, but all the true-believers said Obamacare wouldn't affect the doctor-patient... MORE
"The Centers for Medicare and Medicaid Services said that status is no longer... MORE
So, the first shoe drops on the billions raided from Medicare in order to fund... MORE

advertising

WASHINGTON — In a move that some fear could compromise care for Medicare recipients, the Obama administration is proposing to remove special protections that guarantee seniors access to a wide selection of three types of prescription drugs.

Some advocates for patients are criticizing the idea, but the Medicare prescription benefit’s first administrator says greater availability of generic drugs nowadays may allow for some protections to be safely eased.

The three classes of drugs — widely used antidepressants, antipsychotics and drugs that suppress the immune system to prevent the rejection of a transplanted organ — have enjoyed special “protected” status since the launch of the Medicare prescription benefit in 2006.

That has meant that the private insurance plans that deliver prescription benefits to seniors and disabled beneficiaries must cover “all or substantially all” medications in the class, allowing broad access.

The plans can charge more for costlier drugs, but they can’t just close their lists of approved drugs, or formularies, to protected medications.

In a proposal published Friday in the Federal Register, the administration called for removing protected status from antidepressants, antipsychotics and immunosuppressant drugs.

The Centers for Medicare and Medicaid Services said that status is no longer needed to guarantee access, and the change would save millions of dollars for taxpayers and beneficiaries alike, while potentially helping with the problem of improperly prescribed antipsychotic drugs in nursing homes.

Advocates for patients are opposed, saying it could potentially limit access to critically needed medications for millions of people.

“We are disturbed by this,” said Andrew Sperling, legislative advocacy director for the National Alliance on Mental Illness.

Sperling said that patients with mental-health problems often have to try a variety of drugs before they find the right one for their condition. He questioned whether the change would help crack down on the problem of improperly prescribed antipsychotics.

National Kidney Foundation officials also voiced worries. Legislative policy director Tonya Saffer said transplant patients often depend on combinations of medication, so having the broadest possible choice is crucial.

“Covering all immunosuppressant drugs is very important for the patient and very important to protect the transplanted organ from rejection,” Saffer said.

Medicare’s prescription-drug coverage has proved a popular benefit since it was added under President George W. Bush.

The first administrator of the program, health-policy expert Mark McClellan, says it may make sense to ease some patient protections because there are more low-cost generic alternatives now than was the case eight years ago.

But he said the government has to be careful to find the right balance.

Three other types of drugs that have special status — for cancer, HIV/AIDS and preventing seizures — would remain protected.

If adopted in the coming months, the new policy could take effect as early as 2015 — with an additional year to make the change for antipsychotic medications.

The administration estimates the plan could save the taxpayers a total of $720 million by 2019. Beneficiaries may also be able to save.

That’s because the drug plans can drive a harder bargain for manufacturer discounts when a drug is not protected.

A leading industry analyst said the proposal would represent a significant change for Medicare’s prescription benefit.

“It is a weakening of a patient protection,” said Dan Mendelson, chief executive of Avalare Health, a market-analysis firm.

“I’m not sure that Medicare saves money from this kind of a change,” he added.



News where, when and how you want it

Email Icon

Seattle Sketcher Book

Seattle Sketcher Book

Take home the Seattle Sketcher's latest book! Available now.

Advertising

Partner Video

Advertising

The Seattle Times Historical Archives

Browse our newspaper page archives from 1900-1984


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►